At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
buprenorphinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessing the Safety of Buprenorphine in People With Sickle Cell Disease
In Brief
A Phase 2 clinical trial evaluating buprenorphine for Sickle Cell Disease. Completed, enrolled 47 participants across 1 site.
Detailed Summary
This study will assess the safety of changing pain medications (opioids) adult sickle cell patients take to another type of medication therapy (buprenorphine). Patients will be asked questions about their quality of life. Other tools for assessment will also be administered.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartAug 2018
Primary CompletionSep 2019
Study CompletionFeb 2022
TodayJul 2026
First PostedApr 10, 2018
Enrollment StartAug 1, 2018
Primary CompletionSep 23, 2019
Study CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.2 years ago
Interventions
buprenorphinedrug
Patients in this study will receive dosages to be determined by a physician that are specific to each patient.